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Docosahexaenoic Acid Supplementation, Vascular Function and
Risk Factors for Cardiovascular Disease: A Randomized
Controlled Trial in Young Adults
Atul Singhal, MD, MRCP; Julie Lanigan, PhD, RD; Clare Storry, BSc; Sarah Low, BSc; Toni Birbara, BAppSci; Alan Lucas, MD, FRCP, FMed
Sci; John Deanﬁeld, FRCP
Background-—A high consumption of omega-3 long-chain polyunsaturated fatty acids, and particularly docosahexaenoic acid
(DHA), has been suggested to reduce the risk of cardiovascular disease (CVD). However, while DHA supplementation may have
beneﬁts for secondary prevention, few studies have investigated the role of DHA in the primary prevention of CVD. Here, we tested
the hypothesis that DHA supplementation improves endothelial function and risk factors for CVD.
Methods and Results-—Healthy volunteers (n=328), aged 18 to 37 years, were randomly assigned to 1.6 g DHA/day (from a
microalgae source) together with 2.4 g/day carrier oil (index group) or to 4.0 g/day olive oil (control) (both given in eight 500-mg
capsules/day for 16 weeks). Flow-mediated endothelium-dependent vasodilation (FMD) of the brachial artery (primary outcome)
was measured before and after the intervention (n=268) using high-resolution vascular ultrasound. FMD was the same in both
groups at randomization (mean, SD; 0.27, 0.1 mm), but postintervention was higher in the control group (0.29, 0.1 mm) compared
with the DHA-supplemented group (0.26, 0.1 mm; mean difference 0.03 mm; 95% CI 0.005 to 0.06 mm; P=0.02). Of other
outcomes, only triglyceride (mean difference 28%, 95% CI 40% to 15%; P<0.0001) and very low-density lipoprotein
concentrations were signiﬁcant lower in DHA-supplemented individuals compared with controls.
Conclusions-—DHA supplementation did not improve endothelial function in healthy, young adults. Nevertheless, lower triglyceride
concentrations with DHA supplementation was consistent with previous reports and could have beneﬁts for the prevention of CVD.
Clinical Trial Registration Information-—URL: http://www.controlled-trials.com/ Unique identiﬁer: ISRCTN no: 19987575. ( J
Am Heart Assoc. 2013;2:e000283 doi: 10.1161/JAHA.113.000283)
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A high intake of long-chain omega-3 polyunsaturated fattyacids (n-3 LC-PUFAs) ecosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) has been shown to reduce the
risk of cardiovascular disease (CVD) in both epidemiological
studies1,2 and randomized controlled trials (RCTs).2,3 How-
ever, previous RCTs have largely focused on secondary
prevention in high-risk patients,3 and relatively few studies
have investigated the role of n-3 LC-PUFAs in the primary
prevention of CVD.2
Beneﬁcial effects of n-3 LC-PUFA supplementation on
inﬂammatory makers,4,5 serum risk factors for CVD,4,5 blood
pressure,6 lipid concentrations,4,5,7,8, and particularly endo-
thelial function,9–24 a key early stage in the vascular biology of
atherosclerosis,25 support their potential role in the preven-
tion of CVD. Supplementation with n-3 LC-PUFAs has been
shown to improve endothelial function in healthy middle-aged
adults17 and in patients with hypercholesterolemia,11,12,15
hyperlipidemia,14,18,20 type 2 diabetes,10 coronary heart
disease,13,22 or following heart transplants.9 However, rela-
tively few studies have investigated the effects of n-3
LC-PUFAs on endothelial function in healthy young popula-
tions,16,19,21,24 early in the clinical development of athero-
sclerotic disease.
Previously, red cell DHA concentration was associated with
greater ﬂow-mediated endothelial-dependent vasodilation
(FMD) of the brachial artery in healthy adults who smoked,
who were in the top thirds of cardiovascular risk factors such
as fasting insulin, glucose, or plasma triglyceride concentra-
tion,16 and plasma n-3 LC-PUFA levels were associated with
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greater FMD in carriers for the Glu298ASP polymorphism (an
allele in the gene that encodes for vascular endothelial nitric
oxide synthase, which is postulated to affect adversely
endothelial function and CVD risk26). Furthermore, epidemi-
ological associations between dietary intakes of n-3 LC-PUFA
and lower levels of inﬂammation and endothelial activation27
suggest that high n-3 LC-PUFA consumption may have a role
in the prevention of early vascular disease. Nevertheless,
previous n-3 LC-PUFA supplementation studies in healthy
populations have been small17,19 and shown inconsistent
ﬁndings21,23,24 and few have been conducted in healthy young
adults who may take n-3 LC-PUFA supplements to reduce
CVD risk.
In the present study, we investigated the impact of n-3
LC-PUFA supplementation on brachial artery FMD (primary
outcome), surrogate vascular markers for atherosclerosis,28,29
and conventional biochemical risk factors for CVD in healthy
young adults. We focused only on the effects of DHA
supplementation, which has been suggested to have greater
beneﬁts for endothelial function14,16,17 and CVD risk factors30
than EPA, and used a dose within the normal dietary range
(equivalent to 1 portion of oily ﬁsh per day for total n-3
LC-PUFA).
Methods
Study Population
Healthy volunteers (N=328) were recruited from participants
in a previous study16 and from adverts placed in local
newspapers and around University College London. Individu-
als who were aged 18 to 37 years, clinically well at the clinic
visit, and free from chronic disease likely to affect endothelial
function (eg, insulin-dependent diabetes) were eligible. Those
who were pregnant, on unusual diets, or taking regular
medication or n-3 LC-PUFA supplements were excluded. All
participants gave written consent, and the study was
approved by a National Research Ethics Committee. The trial
was registered on Current Controlled Trials (ISRCTN No.
19987575) (http://www.controlled-trials.com/ISRCTN199875
75/singhal).
Study Design
The study was a double-blind, parallel-group, placebo-
controlled randomized trial conducted at the Childhood
Nutrition Research Centre, UCL, London, between 2003 and
2008. Participants were randomly assigned to DHA supple-
mentation or control groups using a randomization list
generated by an independent statistician and held at a
collaborating center (Martek, Biosciences Corporation,
Columbia, MD, now DSM Nutritional Lipids). To ensure that
the control and index groups were similar with respect to
smoking status, or the Glu298Asp polymorphism for the
eNOS gene (as suggested previously26) randomization was
stratiﬁed by eNOS polymorphism (Glu298 homozygotes,
Asp298 heterozygotes, and Asp298 homozygotes) and
smoking status (current smoker or not). The assigned
dietary group was allocated using numbered, sealed,
and opaque envelopes, and all participants and research
staff were blind to the dietary assignment. Endothelial
function and other study outcomes were measured during a
1-day visit to the research center before and after
4 months of dietary intervention. All subjects were asked
to participate in postintervention measurements regardless
of whether they complied with the study protocol (intention
to treat).
Supplementation
Participants were randomized to 1.6 g DHA/day with 2.4 g/
day carrier oil (predominantly palmitic acid [16:0], myristic
acid [14:0], and the omega-6 fatty acid, docosapentaenoic
[22:5n-6]) or to 4.0 g/day olive oil (control). Supplements
were given as eight 500-mg gelatin capsules each day with
each capsule providing 200 mg DHA in the index group. DHA
was from a microalgae source (Schizochytrium sp), and all
capsules were provided by Martek Biosciences Corporation.
The proposed level of supplementation was chosen because
it is approximately equivalent to the total n-3 LC-PUFA intake
from a portion of oily ﬁsh (eg, herring or salmon) per day
(and therefore within the normal dietary range for the
population).31 Supplementation of less than 3 g of n-3
LC-PUFA per day has been categorized as generally regarded
as safe (GRAS) by the US Food and Drug Administration.31
Olive oil was chosen as the control supplement because
saturated fatty acids have been suggested to have a
detrimental effect on vascular function, while oils rich in
n-6 fatty acids were likely to compete for D5-desaturase
needed to form DHA.
Compliance with dietary supplements was encouraged by
weekly phone calls and text messages and monitored by
counting the number of capsules consumed by the end of the
intervention. Information on any serious adverse events was
also recorded during these calls. Data on adverse effects and
tolerance were recorded for the preceding 7 days during
monthly phone calls. Red cell concentrations of n-3 LC-PUFAs
before and after the intervention were used as an objective
measure of compliance.
Vascular Study Outcomes
All studies were performed in a temperature-controlled (22°C
to 26°C) vascular laboratory by 1 of 2 trained operators.
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Subjects had fasted overnight and rested for 10 minutes
before measurements were taken.
Brachial artery vasomotor function
The principal trial outcome was FMD of the brachial artery
measured as described previously.16,32 Brieﬂy, the brachial
artery was imaged in longitudinal section, 5 to 10 cm above
the antecubital fossa, using high-resolution ultrasound
(GE Vivid 7; General Electric Healthcare Technologies). A pneu-
matic cuff was inﬂated around the forearm to 300 mm Hg for
5 minutes followed by rapid deﬂation causing a large
increase in blood ﬂow (reactive hyperemia). Brachial artery
diameter was measured with edge detection software
(Brachial Tools; MIA) from electrocardiogram (ECG)-triggered
images captured every 3 seconds throughout the 11-minute
recording protocol (for 1 minute resting, 5 minutes cuff
inﬂation, and 5 minutes post cuff deﬂation). Reactive hyper-
emia was calculated from the maximal ﬂow (recorded
continuously by pulsed-wave Doppler) within the ﬁrst 15 sec-
onds after deﬂation of the pneumatic cuff, relative to baseline
ﬂow. FMD was expressed as the absolute maximal change
between prehyperemic and posthyperemic brachial artery
diameter adjusted for prehyperemic diameter using regres-
sion analysis and as a percent change from baseline arterial
diameter.32 Absolute change in diameter was chosen as the
primary outcome because it is independent of baseline
arterial diameter, which contributes to sex differences in
FMD expressed as a percent change.32
Brachial artery distensibility
Brachial artery distensibility was assessed on the arterial
segment subsequently imaged for FMD measurement (see
earlier).32 Real-time B-mode images were recorded on video
for 20 seconds and used for later ofﬂine analysis. The
distention of the artery was determined by measuring the
luminal diameter excursion from diastole to systole and
expressed as a percentage of baseline diameter.32 Blood
pressure was measured in the left brachial artery using an
automated device (Accutorrsat; Datascope Corp) during
distention measurement in the right arm. This provided a
representative measure of the pulse pressure in the right
brachial artery, which was used to derive distensibility
coefﬁcient as the change in cross-sectional area per unit
change in blood pressure as described previously.33 Blood
pressure was also determined on 2 occasions before the
measurement of arterial distensibility after 10 minutes resting
supine. The mean of the 3 measurements was used to assess
effects of DHA supplementation on systolic, diastolic, and
mean arterial blood pressures. Due to technical difﬁculties at
the start of the trial, brachial artery distensibility was not
measured in the ﬁrst 114 (of 324) participants.
Carotid artery distensibility
The carotid artery was imaged using B-mode ultrasonography
at a region 1 cm proximal to the bifurcation of the right and
left common carotid arteries. The transducer was manipulated
such that the near wall of the carotid artery was parallel to the
transducer footprint and the lumen was maximized in the
longitudinal plane. Real-time B-mode images were recorded
on video for 20 seconds and used for later ofﬂine analysis
with edge detection software (Brachial Tools/Carotid Ana-
lyzer; MIA). Brachial blood pressure was recorded at 5-minute
intervals throughout the period of ultrasound scanning. The
artery diameter changes for assessing carotid distensibility
and the distensibility coefﬁcient were analyzed as described
previously.33
Carotid artery intima–media thickness
The common carotid was imaged 1 cm proximal to the
bifurcation. Longitudinal images of the far wall intima–media
interface was clearly deﬁned and recorded on videotape for
later analysis. The distance between the leading edge of the
intima and the media–adventitia was measured with ultra-
sonic calipers. Three measurements were taken in both the
right and left common carotid arteries, and mean intima–
media thickness (IMT) was calculated as described previ-
ously.34
Pulse wave velocity
Pressure-pulse wave signals were recorded using an applica-
tion tonometer (SphygmoCor; AtCor Medical) positioned at
the base of the right common carotid artery and over the right
radial artery. Pressure-pulse wave signals were recorded with
an ECG signal, which provided an R-timing reference. Integral
software processed each set of pulse pressures using ECG
waveform data to calculate the mean time difference between
the R waves and the pressure waves on a beat-to-beat basis
over 10 seconds. Pulse wave velocity was calculated using
the mean time difference and arterial path length between the
2 recording points.32
Anthropometry, Biochemistry, and Fatty Acid
Analysis
Height and weight were measured using standard equipment
and protocols. Socioeconomic class was based on the
participant’s occupation according to the Registrar General’s
Classiﬁcation. Smoking and alcohol consumption were
recorded in a brief lifestyle questionnaire and by salivary
cotinine measurements. Blood was obtained via venipuncture
between 9:00 AM and 11:00 AM after an overnight fast, and
plasma concentrations of cardiovascular risk factors were
determined in the laboratories of Great Ormond Street
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Hospital using standard laboratory methods. Red cell and
plasma concentrations of the n-3 LC-PUFAs were determined
before and after the intervention using standardized methods
in the laboratories of Professor von Schacky35,36 and
expressed as a percentage of total fatty acids.
Sample Size
The minimum projected sample size was calculated as 256
subjects (128 each in n-3 LC-PUFA–supplemented and control
groups). This was sufﬁcient to detect a 0.35-SD difference in
FMD (primary outcome) between randomized groups at 5%
signiﬁcance and with 80% power, an effect considerably
smaller than the 1-SD increase in FMD with ﬁsh oil
supplementation shown previously in healthy volunteers.19
Successful recruiting meant that 324 subjects were random-
ized and 274 completed the intervention.
Statistical Analysis
Student t test was used compare randomized groups for
normally distributed variables, and v2 test was used for
dichotomous variables. Initial analyses were on an inten-
tion-to-treat basis. Linear regression was used to investigate
the effect of randomized diets on absolute change in FMD
adjusted for baseline arterial diameter. The distributions of
fasting very low-density lipoprotein (VLDL), triglyceride, insu-
lin, C-reactive protein (CRP), and cotinine concentrations and
sum of skinfold thickness were right skewed and so were loge
transformed and then multiplied by 100 before analysis.37 The
SD for 100 loge transformed data represents the coefﬁcient of
variation of the original data, while regression coefﬁcients
represent the percentage difference in dependent variable per
unit change in the independent variable.37
In secondary analyses, multiple linear regression was used
to adjust differences in absolute FMD between randomized
groups for potential confounding factors (age, sex, room
temperature, skin temperature, and fasting concentrations of
LDL and triglycerides). A priori planned analyses included
investigating the effects of DHA supplementation on FMD
according to sex, smoking status, presence of Asp298 allele,
and CVD risk factors (ie, in individuals in the highest third of
fasting concentrations of insulin, glucose, or triglyceride16).
All analyses were conducted using SPSS for Windows (version
18.0; SPSS Inc), and statistical signiﬁcance was taken as
P<0.05.
Results
Demographic factors, measures of vascular structure and
function, and risk factors for CVD (eg, body mass index [BMI]
and lipid concentration) were similar to those for the general
young adult population in the United Kingdom at the time of
the study16 (Table 1). Of the 328 subjects recruited, 4
dropped out before randomization, 324 were randomized to
DHA or control supplements, and 274 were reviewed 4
months after the start of the study (Figure 1).
Control and DHA-supplemented groups were closely
matched for demographic, anthropometric, and socioeco-
nomic variables; biochemical cardiovascular risk factors; and
vascular measures at baseline (Tables 1 and 2). There was
evidence to suggest high compliance with DHA supplemen-
tation. DHA-supplemented individuals had higher red cell DHA
concentration at follow-up than did control subjects (Table 3),
and more individuals in the DHA-supplemented group (87%,
n=114/130) had an increase in their red cell omega-3 index35
([DHA+EPA]/total fatty acids) compared with controls (53%,
n=70/130) (P<0.0001).
The study completion rates were high (>80%) for both
randomized groups and sexes (Figure 1 and Table 3). Indi-
viduals who did not complete the study did not signiﬁcantly
differ from those who did in age, sex, anthropometry,
socioeconomic status, vascular measures such as blood
pressure or FMD, baseline biochemistry, or red cell DHA
concentrations (data not presented).
There were no serious adverse events in either dietary
group and both diets were well tolerated. No participant
dropped out of the study due to adverse effects associated
with either dietary supplement (the most common reason for
dropping out was social). Tolerance data were obtained in 133
and 129 participants from control and DHA-supplemented
groups, respectively. Most study participants did not experi-
ence any adverse events (86/133 and 84/129 in control and
DHA-supplemented groups, respectively). The most common
problems were gastrointestinal, but the incidence of these
was similar in both randomized groups (23% [n=31/133] and
25% [n=32/129] in control and DHA-supplemented groups,
respectively) (for speciﬁc symptoms in control and DHA-sup-
plemented groups, respectively: abdominal pain, n=3 and 5;
nausea, n=2 and 5; bloating, n=6 and 7; ﬂatulence, n=12 and
9; diarrhea, n=4 and 4; and constipation, n=4 and 2).
Compared with controls, absolute FMD of the brachial
artery adjusted for baseline diameter was signiﬁcantly lower
in the DHA-supplemented group (mean difference 0.03 mm,
95% CI 0.005 to 0.06 mm, P=0.02) (Table 4). This
difference remained after further adjustment for potential
confounding factors (age, sex, skin temperature, room
temperature. and fasting concentrations of LDL cholesterol
and triglycerides) (mean difference 0.03 mm, 95% CI
0.005 to 0.06 mm, P=0.02). Randomized groups did not
differ in other vascular outcomes, blood pressure, or fasting
concentrations of insulin, glucose, or CRP (Table 4). However,
fasting concentrations of VLDL and triglycerides were lower in
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the DHA-supplemented compared with the control group
(mean difference for VLDL: 28%, 95% CI 40% to 15%,
P<0.0001; mean difference for triglycerides: 28%, 95% CI
40% to 15%, P<0.0001). Similar ﬁndings were obtained
using nonparametric statistics for both VLDL (median, inter-
quartile range: 0.4, 0.3 to 0.5 mmol/L in controls versus 0.3,
0.2 to 0.4 mmol/L in DHA supplemented; Mann–Whitney
U test: P<0.0001) and triglyceride concentration (median,
interquartile range: 0.8, 0.6 to 1.2 mmol/L in controls versus
0.6, 0.4 to 0.9 mmol/L in DHA-supplemented; Mann–Whitney
U test: P<0.0001).
In secondary analyses, the lower FMD with DHA supple-
mentation was shown to be conﬁned to men (Table 4)
(randomized dietary group9sex interaction: P=0.01). Simi-
larly, compared with controls, blood pressure was lower in
DHA-supplemented men but not women (Table 4) (P values
Table 1. Subject Characteristics at Baseline
Control DHA Supplemented
All Male Female All Male Female
N 162 162
Sex,* %, n 40 65 60 97 34 55 66 107
Age, y 27.6 4.7 29.0 4.6 26.6 4.5 28.2 4.8 28.8 4.8 27.9 4.7
Social class*
Manual, %, n 42 68 35 23 46 45 44 71 54 30 38 41
Nonmanual, %, n 58 94 65 42 54 52 56 91 45 25 62 66
Current smoker,* %, n 14 23 12 8 15 15 13 20 9 5 14 15
Weight, kg 68.9 13.4 76.7 11.7 63.7 11.9 67.4 14.1 75.1 9.8 63.5 14.4
Height, cm 170.5 9.3 177.9 8.0 165.6 6.5 168.9 9.0 176.7 6.6 165.0 7.4
Body mass index, kg/m2 23.6 3.5 24.2 2.8 23.2 3.9 23.6 4.3 24.1 3.2 23.3 4.8
Sum skinfold,†‡ mm 48.4 39 42.3 39 53.0 36 46.4 43 38.7 43 51.0 41
Waist circumference, cm 77.5 9.7 83.6 8.0 73.4 8.5 77.1 10.6 83.0 8.4 74.0 10.3
Waist:hip ratio 0.8 0.07 0.8 0.05 0.7 0.05 0.8 0.07 0.8 0.06 0.8 0.05
Blood pressure, mm Hg
Systolic 113 11 118 10 109 10 111 11 114 8 109 11
Diastolic 67 8 69 8 65 7 67 8 68 7 66 8
Mean arterial 84 9 88 9 81 8 83 8 86 6 82 9
Pulse pressure 46 6 49 6 44 6 44 6 47 6 44 6
Resting heart rate, beats/min 66 9 65 10 67 8 66 10 63 8 67 10
Total cholesterol, mmol/L 4.2 0.9 4.3 0.9 4.1 0.9 4.3 0.8 4.4 0.8 4.3 0.8
LDL cholesterol, mmol/L 2.3 0.8 2.5 0.8 2.2 0.8 2.4 0.7 2.6 0.7 2.3 0.7
HDL cholesterol, mmol/L 1.4 0.3 1.3 0.3 1.5 0.3 1.5 0.4 1.3 0.3 1.5 0.4
VLDL cholesterol,† mmol/L 0.4 50 0.4 56 0.4 46 0.4 50 0.4 55 0.4 46
Total:HDL cholesterol ratio 3.1 1.0 3.6 1.0 2.8 0.9 3.1 1.0 3.5 1.0 2.9 0.9
LDL:HDL cholesterol ratio 1.8 0.8 2.1 0.9 1.5 0.7 1.8 0.8 2.1 0.7 1.6 0.8
Triglyceride,† mmol/L 0.8 50 0.9 55 0.8 46 0.9 50 0.9 55 0.8 46
Glucose, mmol/L 4.8 0.5 5.0 0.5 4.7 0.4 4.8 0.5 4.9 0.5 4.7 0.5
Insulin,† mU/L 25.5 58 24.3 58 26.4 58 25.9 61 23.8 58 27.0 62
Insulin resistance† (HOMA), lm/L 0.8 61 0.7 63 0.8 61 0.8 66 0.7 64 0.8 67
CRP,† mg/L 0.9 120 0.8 108 1.0 128 1.0 122 0.8 126 1.2 120
Cotinine,† ng/mL 1.8 261 2.0 280 1.6 250 1.5 249 1.2 266 1.6 242
Data are mean, SD except *% (n) and †geometric mean (coefﬁcient of variation). There is <5% loss of n for some variables. DHA indicates docosahexaenoic acid; LDL, low-density
lipoprotein; HDL, high-density lipoprotein; VLDL, very low-density lipoprotein; HOMA, homeostatic model assessment; CRP, C-reactive protein.
‡Measured at 4 sites: triceps, biceps, subscapular, and suprailiac.
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for randomized group9sex interaction for all measures of
blood pressure were <0.04). However, there was no evidence
to suggest that FMD varied according to smoking status,
being an Asp298 carrier, or according to risk factors for CVD
at baseline (randomization) (data not presented). The effect of
DHA supplementation on fasting triglyceride concentration
was independent of sex (randomized dietary group9sex
interaction: P=0.9) but was greater in those with a higher
triglyceride concentration at baseline (randomized dietary
group9triglyceride concentration at baseline interaction:
P=0.04).
Analysis of intraindividual change in FMD between visit 2
(postintervention) and visit 1 (baseline), showed that FMD fell
in the DHA supplemented group (mean, SD: 0.34, 3.5%) but
increased in the control group (0.47, 3.4%) (mean difference
between groups for intraindividual change in FMD%: 0.80%;
95% CI: 1.6% to 0.02%; P=0.05). Similar data were obtained
when conﬁning the analysis to men (intraindividual change
in FMD% in DHA supplemented group: mean, SD: 0.6, 2.6%
compared with controls: 0.8, 3.1%; mean difference between
groups: 1.5%; 95% CI 2.6% to 0.4%, P=0.01). There were
no signiﬁcant differences between randomized groups for the
intraindividual change in FMD in women (data not presented).
In nonrandomized, epidemiological analyses, for the study
population as a whole, there was a dose–response association
Figure 1. Flowchart of participants through trial. DHA indicates
docosahexaenoic acid; FMD, ﬂow-mediated endothelium-dependent
vasodilation.
Table 2. Vascular Variables at Baseline
Control DHA Supplemented
All Male Female All Male Female
N 162 65 97 162 55 107
Brachial artery
Diameter, mm 3.2 0.6 3.7 0.4 2.8 0.3 3.2 0.6 3.8 0.4 2.9 0.4
Reactive hyperemia % 713 249 613 232 778 240 759 276 665 216 808 292
Flow-mediated dilation, mm 0.27 0.1 0.27 0.1 0.27 0.1 0.27 0.1 0.26 0.1 0.28 0.1
Flow-mediated dilation, % 8.3 3.7 7.1 3.3 9.1 3.7 8.5 3.7 6.8 3.2 9.3 3.7
Distention,* mm 0.08 0.04 0.09 0.04 0.08 0.04 0.09 0.04 0.1 0.04 0.09 0.04
Distention,* % 11.4 5.4 10.0 3.8 12.5 6.1 13.2 5.8 11.1 4.3 14.0 6.1
Distensibilty coefficient,* 9103 kPa1 8.4 3.9 7.3 2.7 9.2 4.4 9.8 4.7 8.8 5.5 10.3 4.2
Right common carotid
Diameter, mm 6.5 0.5 6.8 0.5 6.3 0.5 6.5 0.5 6.8 0.5 6.3 0.4
Distention, mm 0.7 0.1 0.7 0.2 0.7 0.1 0.7 0.2 0.7 0.2 0.7 0.1
Distention, % 11.6 2.4 11.0 2.5 12.0 2.4 11.1 2.7 11.1 3.4 11.2 2.4
Distensibilty coefficient, % (9103 kPa1) 33.8 7.3 30.3 6.2 36.3 7.0 34.5 10.3 33.0 14.4 35.3 7.5
Carotid intima–media thickness, mm 0.54 0.08 0.56 0.1 0.53 0.07 0.54 0.07 0.56 0.08 0.54 0.07
Carotid–radial PWV, m/s 8.6 1.2 8.9 1.1 8.3 1.2 8.6 1.4 8.6 1.2 8.6 1.4
Data are mean, SD except: mean, SD, and range. There is <5% loss of n for some variables. DHA indicates docosahexaenoic acid; PWV, pulse wave velocity.
*N=110 in control and DHA-supplemented groups.
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between red cell DHA concentration and fasting triglyceride
concentration (using regression analyses with loge9100
transformed data,37 there was a 4.1% change in triglyceride
concentration, per 1% increase in red cell DHA concentration;
95% CI 1.6% to 6.6%, P=0.002) but not for FMD (data not
presented).
Discussion
A high dietary intake of n-3 LC-PUFA is thought to reduce the
risk of CVD, but evidence to support its advantages in healthy
populations is relatively scarce.2 In the present study, we
investigated the impact of 4 months’ DHA supplementation on
endothelial function and surrogate vascular measures of
atherosclerosis and found no evidence to support a beneﬁcial
effect on these key cardiovascular outcomes. In fact,
unexpectedly, DHA supplementation appeared to have a
small but signiﬁcant negative effect on endothelial function in
men. However, DHA supplementation had favorable effects on
blood pressure in men and triglyceride concentration in both
sexes. These data therefore raise the possibility that the
advantages of a high DHA intake for the primary prevention of
CVD1,2 are not a consequence of its effects on endothelial
function, but act via beneﬁts on other risk factors for CVD.
Enhancement of endothelial function has been suggested
as a key mechanism for the protective effect of n-3 LC-PUFAs
on the development of atherosclerosis.9–24 However, most
previous RCTs have been conducted in patients at high CVD
risk and relatively few studies have investigated healthy
individuals. Previously, supplementation of 5 g/day of tuna oil
for 8 months was shown to improve endothelial function, as
measured in forearm skin using laser Doppler, by 17%,17
whereas supplementation with 1 g/day ﬁsh oil for 14 days
improved both endothelium-dependent and endothelium-inde-
pendent vasodilation of the brachial artery in healthy adults.19
Our data are inconsistent with these reports possibly because
these studies were small,17,19 did not have a parallel RCT
design,17 investigated endothelial function in resistance
vessels (which may correlate poorly with FMD of conduit
vessels such as the brachial artery),17 or were conducted in
older adults, who are more likely to have subclinical
atherosclerosis and impairment of endothelial function.17
However, our ﬁndings are consistent with a recent RCT that
found no effect of up to 1.8 g/day n-3 LC-PUFA supplemen-
tation on FMD in middle-aged adults at moderately increased
CVD risk.23 Similarly, in a cross-sectional analysis in 3045
adults aged 45 to 84 years, the highest quartile of nonfried
ﬁsh consumption was associated with a 1-SD lower brachial
artery diameter in men and 0.27% smaller FMD in women,
Table 3. Red Blood Cell Fatty Acid Concentrations Preintervention and Postintervention
Control DHA Supplemented
Comparison of Randomized Groups
(P Value)
All Male Female All Male Female All Male Female
N*
Preintervention 156 65 91 160 54 106
Postintervention 135 56 79 131 50 81
Docosohexenoic acid,† %
Preintervention 5.3 1.7 5.2 1.8 5.3 1.6 5.5 1.7 5.3 1.8 5.6 1.6 0.3 0.8 0.3
Postintervention 5.3 1.8 5.1 1.8 5.4 1.7 8.9 2.6 8.8 2.7 8.9 2.5 <0.0001 <0.0001 <0.0001
Eicosapentenoic acid,† %
Preintervention 1.0 0.6 1.1 0.6 0.9 0.5 1.0 0.5 1.0 0.6 1.0 0.5 0.7 0.5 0.2
Postintervention 0.9 0.5 1.0 0.5 0.9 0.5 1.3 0.6 1.2 0.6 1.4 0.6 <0.0001 0.01 <0.0001
Omega-3 index†
Preintervention 6.2 2.1 6.2 2.3 6.3 2.0 6.5 2.1 6.3 2.3 6.6 2.0 0.3 0.9 0.2
Postintervention 6.2 2.2 6.1 2.2 6.3 2.2 10.2 3.0 10.0 3.1 10.3 2.9 <0.0001 <0.0001 <0.0001
Omega 3 index ≥8%, ‡%, n
Preintervention 19 30 17 11 21 19 22 35 22 12 22 23 0.3 0.3 0.5
Postintervention 16 22 16 9 16 13 76 100 70 35 80 65 <0.0001 <0.0001 <0.0001
DHA indicates docosahexaenoic acid; omega-3 index, docosahexenoic+eicosapentenoic/total fatty acids.
*Red cell fatty acids concentrations were successfully obtained in 98% (316/324) of participants at randomization and 97% (266/274) postintervention.
†Data are mean, SD % of total fatty acids except ‡percent and number of individuals.
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compared with the lowest quartlie.38 Collectively, therefore,
together with these previous reports,23,38 our data support
the hypothesis that although n-3 LC-PUFA supplementation
may improve endothelial function in individuals with clinical
CVD disease13,22 or risk factors such as dyslipidemia and type
2 diabetes,10,21 there is little evidence to suggest a beneﬁcial
effect on endothelial function in healthy young adults.
The possible detrimental effect of DHA supplementation on
FMD in men was an unexpected ﬁnding and requires further
investigation. Few previous RCTs have been adequately
powered to detect sex differences in effects of n-3 LC-PUFAs
on endothelial function. However, n-3 LC-PUFA supplementa-
tion has been shown to increase the concentration of soluble
e-selectin, a marker of endothelial activation, in younger
compared with older men.39,40 Moreover, both n-3 LC-PUFA
metabolism and the association between ﬁsh intake and
vascular function38 have been shown to vary by sex. Women
have greater tissue DHA content than men41 and a higher
capacity to metabolize a-linolenic acid to DHA.42 The clinical
implications of these sex differences is unclear, but our
ﬁnding of 20% lower FMD in DHA-supplemented men,
together with earlier data showing detrimental effects of n-3
LC-PUFA on endothelial activation in men,39,40 suggests that
future trials of n-3 LC-PUFA need to be powered to detect
possible sex differences in cardiovascular outcomes.
As in previous reports, we found no effect of DHA
supplementation on vascular measures such as carotid
IMT29 and arterial stiffness,23 or on CVD risk factors such
as CRP concentration.5 There was, however, a small beneﬁt of
DHA supplementation on mean arterial blood pressure in men
but not in women. Although the reasons for the sex difference
are uncertain, our data are consistent with earlier studies and
meta-analyses,6 which showed that low to moderate doses of
DHA can lower blood pressure in healthy, normotensive
individuals without changes in endothelial function or arterial
stiffness.43
Consistent with previous reports, DHA supplementation
reduced triglyceride concentration.5,7,8 However, importantly,
this effect was seen in a healthy, young population with
triglyceride levels in the normal range. The size of the effect
(27% lower triglyceride concentration) was similar to data
from systematic reviews in older adults5,7,8 that investigated
higher n-3 LC-LCPUFA doses (2.6 g/day8). Furthermore, in
contrast to the recent opinion from the European Food Safety
Authority, which suggested that 3 to 4 g/day DHA supple-
mentation reduced triglyceride concentrations (and >2 g/day
DHA was required for a beneﬁcial effect44), we found similar
beneﬁts at lower DHA intakes, within the dietary range for n-3
LC-PUFA consumption. As in older adults, there was also a
dose–response association between red cell DHA and
triglyceride concentration, and a greater beneﬁt of DHA
supplementation in individuals with higher presupplementa-T
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tion triglyceride levels.5,7,8 Although the clinical implications
of lower triglycerides in young adults is uncertain, hypertri-
glyceridemia has been proposed as an independent risk factor
for CVD45,46 and a target for interventions to reduce
cardiovascular risk.47 The cumulative effect of higher DHA
intake on triglyceride levels may therefore help in the primary
prevention of CVD. The mechanisms for this effect are
unknown, but lower VLDL concentration with DHA supple-
mentation in the present study was consistent with the
hypothesis that n-3 LC-PUFAs decrease the hepatic production
of triglyceride-rich particles.5
The main strengths of our study were a parallel-group,
double-blind, RCT design; large sample size; objective evi-
dence of good compliance with dietary intervention; and
objective, validated outcomes such as FMD. However, our
study has several potential limitations. First, we studied a
young population at low risk of CVD in whom DHA supple-
mentation may not improve further an already largely healthy
endothelium. Nonetheless, the study population was similar to
our previous cross-sectional study, which found strong
associations between red cell DHA concentration and brachial
artery FMD,16 and although mean values were within the
normal range, many participants had evidence of endothelial
dysfunction and high levels of CVD risk factors. Moreover, the
lack of any effect of DHA supplementation even in those in
the highest third of the distribution for CVD risk factors,
together with previous data from older adults at moderate
CVD risk,23 suggests that DHA supplementation is unlikely to
improve endothelial function in healthy adults regardless of
underlying cardiovascular risk.
Second, to aid compliance, DHA supplements were given
for only 4 months. Although longer periods of supplementation
may be necessary for effects on some measures of vascular
structure such as carotid IMT,29 previously the effects of n-3
LC-PUFA supplementation on endothelial function have been
suggested in interventions ranging from 2 weeks19 to 8
months.17 Furthermore, for some outcomes such as triglyc-
eride concentration, study duration (between 4 weeks and
2 years) is not associated with the treatment effect, suggest-
ing that maximal effect is achieved after a shorter intervention
and then maintained throughout the intervention period.5
Third, because previous studies suggested stronger effects of
DHA than EPA on vascular function,14,16,17 we supplemented
with only DHA and not also with EPA. However, the indepen-
dent vascular effects of EPA and DHA are poorly understood
and require further investigation.30
Finally, control and index groups differed in both amounts
of DHA and olive oil supplemented and therefore the study
does not exclude an effect of both olive oil and DHA on study
outcomes. For instance, although the effects of different oils
on vascular function are currently inconclusive,48 higher olive
oil intake in the control group could have improved FMD and
contributed to postintervention differences in FMD between
randomized groups. Alternatively, the increase in FMD over the
4-month intervention in the control group may be a conse-
quence of changes to behavior and lifestyle (“Hawthorne
effect”) in individuals motivated by participating in a study of
cardiovascular health. However, neither of these possibilities
invalidates the main observation that DHA supplementation
did not improve endothelial function in this population.
To our knowledge, the present study is the largest RCT to
test the impact of n-3 LC-PUFA supplementation on endo-
thelial function and CVD risk factors in a healthy, young
population. Our data support the hypothesis that higher DHA
consumption has beneﬁts for CVD risk factors such as blood
pressure and triglyceride concentration. However, the effects
of DHA are unlikely to include beneﬁts for endothelial
function, at least with n-3 LC-PUFA intake within the dietary
range.
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